Technology Networks spoke to Dr. Ofer Sharon, CEO of OncoHost, to learn more about the challenges in NSCLC treatment, how proteomics-based analysis could enable personalized cancer treatments and the advantages of a test to predict a patient’s clinical benefit from PD-1/PD-L1 inhibitors.
Read more here.
![[Hailo in GlobeNewswire] Gorilla Technology Group partners with Hailo and Lanner Electronics to build the next-generation Edge AI Appliance](https://blog.ourcrowd.net/wp-content/themes/Extra/images/post-format-thumb-link.svg)
![[Clinch in PR Newswire] Agility selects Clinch as their ad serving and DCO technology partner](https://blog.ourcrowd.net/wp-content/themes/Extra/images/post-format-thumb-text.svg)
